 | • レポートコード：GIR-107A12482 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、95ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、mRNA癌ワクチン・治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。mRNA癌ワクチン・治療の種類別市場規模（腺癌、粘液性癌、腺扁平上皮癌）、用途別市場規模（感染症、がん、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・mRNA癌ワクチン・治療の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Moderna Therapeutics、CureVac、Translate Bio、BioNTech、Sangamo Therapeutics、Argos Therapeutics、In-Cell-Art、eTheRNA、Ethris、Tiba Biotechnology ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：腺癌、粘液性癌、腺扁平上皮癌 ・用途別分析2016年-2026年：感染症、がん、その他 ・mRNA癌ワクチン・治療の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・mRNA癌ワクチン・治療のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・mRNA癌ワクチン・治療のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・mRNA癌ワクチン・治療の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・mRNA癌ワクチン・治療の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The mRNA Cancer Vaccines and Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global mRNA Cancer Vaccines and Therapeutics size is estimated to be USD 229.5 million in 2026 from USD 117.7 million in 2020, with a change XX% between 2020 and 2021. The global mRNA Cancer Vaccines and Therapeutics market size is expected to grow at a CAGR of 18.2% for the next five years.
Market segmentation
mRNA Cancer Vaccines and Therapeutics market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Adeno Carcinomas
Mucinous Carcinomas
Adenosquamous Carcinomas
Market segment by Application, can be divided into
Infectious Disease
Cancer
Others
Market segment by players, this report covers
Moderna Therapeutics
CureVac
Translate Bio
BioNTech
Sangamo Therapeutics
Argos Therapeutics
In-Cell-Art
eTheRNA
Ethris
Tiba Biotechnology
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe mRNA Cancer Vaccines and Therapeutics product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of mRNA Cancer Vaccines and Therapeutics, with revenue, gross margin and global market share of mRNA Cancer Vaccines and Therapeutics from 2019 to 2021.
Chapter 3, the mRNA Cancer Vaccines and Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and mRNA Cancer Vaccines and Therapeutics market forecast, by regions, type and application, with revenue, from 2021 to 2026.
Chapter 11 and 12, to describe mRNA Cancer Vaccines and Therapeutics research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Product Overview and Scope of mRNA Cancer Vaccines and Therapeutics
1.2 Classification of mRNA Cancer Vaccines and Therapeutics by Type
1.2.1 Overview: Global mRNA Cancer Vaccines and Therapeutics Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Type in 2020
1.2.3 Adeno Carcinomas
1.2.4 Mucinous Carcinomas
1.2.5 Adenosquamous Carcinomas
1.3 Global mRNA Cancer Vaccines and Therapeutics Market by Application
1.3.1 Overview: Global mRNA Cancer Vaccines and Therapeutics Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Infectious Disease
1.3.3 Cancer
1.3.4 Others
1.4 Global mRNA Cancer Vaccines and Therapeutics Market Size & Forecast
1.5 Global mRNA Cancer Vaccines and Therapeutics Market Size and Forecast by Region
1.5.1 Global mRNA Cancer Vaccines and Therapeutics Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global mRNA Cancer Vaccines and Therapeutics Market Size by Region, (2016-2021)
1.5.3 North America mRNA Cancer Vaccines and Therapeutics Market Size and Prospect (2016-2026)
1.5.4 Europe mRNA Cancer Vaccines and Therapeutics Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific mRNA Cancer Vaccines and Therapeutics Market Size and Prospect (2016-2026)
1.5.6 South America mRNA Cancer Vaccines and Therapeutics Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa mRNA Cancer Vaccines and Therapeutics Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 mRNA Cancer Vaccines and Therapeutics Market Drivers
1.6.2 mRNA Cancer Vaccines and Therapeutics Market Restraints
1.6.3 mRNA Cancer Vaccines and Therapeutics Trends Analysis
2 Company Profiles
2.1 Moderna Therapeutics
2.1.1 Moderna Therapeutics Details
2.1.2 Moderna Therapeutics Major Business
2.1.3 Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Product and Solutions
2.1.4 Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Moderna Therapeutics Recent Developments and Future Plans
2.2 CureVac
2.2.1 CureVac Details
2.2.2 CureVac Major Business
2.2.3 CureVac mRNA Cancer Vaccines and Therapeutics Product and Solutions
2.2.4 CureVac mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 CureVac Recent Developments and Future Plans
2.3 Translate Bio
2.3.1 Translate Bio Details
2.3.2 Translate Bio Major Business
2.3.3 Translate Bio mRNA Cancer Vaccines and Therapeutics Product and Solutions
2.3.4 Translate Bio mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Translate Bio Recent Developments and Future Plans
2.4 BioNTech
2.4.1 BioNTech Details
2.4.2 BioNTech Major Business
2.4.3 BioNTech mRNA Cancer Vaccines and Therapeutics Product and Solutions
2.4.4 BioNTech mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 BioNTech Recent Developments and Future Plans
2.5 Sangamo Therapeutics
2.5.1 Sangamo Therapeutics Details
2.5.2 Sangamo Therapeutics Major Business
2.5.3 Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Product and Solutions
2.5.4 Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Sangamo Therapeutics Recent Developments and Future Plans
2.6 Argos Therapeutics
2.6.1 Argos Therapeutics Details
2.6.2 Argos Therapeutics Major Business
2.6.3 Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Product and Solutions
2.6.4 Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Argos Therapeutics Recent Developments and Future Plans
2.7 In-Cell-Art
2.7.1 In-Cell-Art Details
2.7.2 In-Cell-Art Major Business
2.7.3 In-Cell-Art mRNA Cancer Vaccines and Therapeutics Product and Solutions
2.7.4 In-Cell-Art mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 In-Cell-Art Recent Developments and Future Plans
2.8 eTheRNA
2.8.1 eTheRNA Details
2.8.2 eTheRNA Major Business
2.8.3 eTheRNA mRNA Cancer Vaccines and Therapeutics Product and Solutions
2.8.4 eTheRNA mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 eTheRNA Recent Developments and Future Plans
2.9 Ethris
2.9.1 Ethris Details
2.9.2 Ethris Major Business
2.9.3 Ethris mRNA Cancer Vaccines and Therapeutics Product and Solutions
2.9.4 Ethris mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Ethris Recent Developments and Future Plans
2.10 Tiba Biotechnology
2.10.1 Tiba Biotechnology Details
2.10.2 Tiba Biotechnology Major Business
2.10.3 Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Product and Solutions
2.10.4 Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Tiba Biotechnology Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global mRNA Cancer Vaccines and Therapeutics Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 mRNA Cancer Vaccines and Therapeutics Players Market Share
3.2.2 Top 10 mRNA Cancer Vaccines and Therapeutics Players Market Share
3.2.3 Market Competition Trend
3.3 mRNA Cancer Vaccines and Therapeutics Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global mRNA Cancer Vaccines and Therapeutics Revenue and Market Share by Type (2016-2021)
4.2 Global mRNA Cancer Vaccines and Therapeutics Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Application (2016-2021)
5.2 mRNA Cancer Vaccines and Therapeutics Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America mRNA Cancer Vaccines and Therapeutics Revenue by Type (2016-2026)
6.2 North America mRNA Cancer Vaccines and Therapeutics Revenue by Application (2016-2026)
6.3 North America mRNA Cancer Vaccines and Therapeutics Market Size by Country
6.3.1 North America mRNA Cancer Vaccines and Therapeutics Revenue by Country (2016-2026)
6.3.2 United States mRNA Cancer Vaccines and Therapeutics Market Size and Forecast (2016-2026)
6.3.3 Canada mRNA Cancer Vaccines and Therapeutics Market Size and Forecast (2016-2026)
6.3.4 Mexico mRNA Cancer Vaccines and Therapeutics Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe mRNA Cancer Vaccines and Therapeutics Revenue by Type (2016-2026)
7.2 Europe mRNA Cancer Vaccines and Therapeutics Revenue by Application (2016-2026)
7.3 Europe mRNA Cancer Vaccines and Therapeutics Market Size by Country
7.3.1 Europe mRNA Cancer Vaccines and Therapeutics Revenue by Country (2016-2026)
7.3.2 Germany mRNA Cancer Vaccines and Therapeutics Market Size and Forecast (2016-2026)
7.3.3 France mRNA Cancer Vaccines and Therapeutics Market Size and Forecast (2016-2026)
7.3.4 United Kingdom mRNA Cancer Vaccines and Therapeutics Market Size and Forecast (2016-2026)
7.3.5 Russia mRNA Cancer Vaccines and Therapeutics Market Size and Forecast (2016-2026)
7.3.6 Italy mRNA Cancer Vaccines and Therapeutics Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific mRNA Cancer Vaccines and Therapeutics Revenue by Type (2016-2026)
8.2 Asia-Pacific mRNA Cancer Vaccines and Therapeutics Revenue by Application (2016-2026)
8.3 Asia-Pacific mRNA Cancer Vaccines and Therapeutics Market Size by Region
8.3.1 Asia-Pacific mRNA Cancer Vaccines and Therapeutics Revenue by Region (2016-2026)
8.3.2 China mRNA Cancer Vaccines and Therapeutics Market Size and Forecast (2016-2026)
8.3.3 Japan mRNA Cancer Vaccines and Therapeutics Market Size and Forecast (2016-2026)
8.3.4 South Korea mRNA Cancer Vaccines and Therapeutics Market Size and Forecast (2016-2026)
8.3.5 India mRNA Cancer Vaccines and Therapeutics Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia mRNA Cancer Vaccines and Therapeutics Market Size and Forecast (2016-2026)
8.3.7 Australia mRNA Cancer Vaccines and Therapeutics Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America mRNA Cancer Vaccines and Therapeutics Revenue by Type (2016-2026)
9.2 South America mRNA Cancer Vaccines and Therapeutics Revenue by Application (2016-2026)
9.3 South America mRNA Cancer Vaccines and Therapeutics Market Size by Country
9.3.1 South America mRNA Cancer Vaccines and Therapeutics Revenue by Country (2016-2026)
9.3.2 Brazil mRNA Cancer Vaccines and Therapeutics Market Size and Forecast (2016-2026)
9.3.3 Argentina mRNA Cancer Vaccines and Therapeutics Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa mRNA Cancer Vaccines and Therapeutics Revenue by Type (2016-2026)
10.2 Middle East & Africa mRNA Cancer Vaccines and Therapeutics Revenue by Application (2016-2026)
10.3 Middle East & Africa mRNA Cancer Vaccines and Therapeutics Market Size by Country
10.3.1 Middle East & Africa mRNA Cancer Vaccines and Therapeutics Revenue by Country (2016-2026)
10.3.2 Turkey mRNA Cancer Vaccines and Therapeutics Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia mRNA Cancer Vaccines and Therapeutics Market Size and Forecast (2016-2026)
10.3.4 UAE mRNA Cancer Vaccines and Therapeutics Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global mRNA Cancer Vaccines and Therapeutics Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global mRNA Cancer Vaccines and Therapeutics Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market mRNA Cancer Vaccines and Therapeutics Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global mRNA Cancer Vaccines and Therapeutics Revenue (USD Million) by Region (2016-2021)
Table 5. Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Region (2021-2026)
Table 6. Moderna Therapeutics Corporate Information, Head Office, and Major Competitors
Table 7. Moderna Therapeutics Major Business
Table 8. Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Product and Solutions
Table 9. Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. CureVac Corporate Information, Head Office, and Major Competitors
Table 11. CureVac Major Business
Table 12. CureVac mRNA Cancer Vaccines and Therapeutics Product and Solutions
Table 13. CureVac mRNA Cancer Vaccines and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Translate Bio Corporate Information, Head Office, and Major Competitors
Table 15. Translate Bio Major Business
Table 16. Translate Bio mRNA Cancer Vaccines and Therapeutics Product and Solutions
Table 17. Translate Bio mRNA Cancer Vaccines and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. BioNTech Corporate Information, Head Office, and Major Competitors
Table 19. BioNTech Major Business
Table 20. BioNTech mRNA Cancer Vaccines and Therapeutics Product and Solutions
Table 21. BioNTech mRNA Cancer Vaccines and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Sangamo Therapeutics Corporate Information, Head Office, and Major Competitors
Table 23. Sangamo Therapeutics Major Business
Table 24. Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Product and Solutions
Table 25. Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Argos Therapeutics Corporate Information, Head Office, and Major Competitors
Table 27. Argos Therapeutics Major Business
Table 28. Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Product and Solutions
Table 29. Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. In-Cell-Art Corporate Information, Head Office, and Major Competitors
Table 31. In-Cell-Art Major Business
Table 32. In-Cell-Art mRNA Cancer Vaccines and Therapeutics Product and Solutions
Table 33. In-Cell-Art mRNA Cancer Vaccines and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. eTheRNA Corporate Information, Head Office, and Major Competitors
Table 35. eTheRNA Major Business
Table 36. eTheRNA mRNA Cancer Vaccines and Therapeutics Product and Solutions
Table 37. eTheRNA mRNA Cancer Vaccines and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Ethris Corporate Information, Head Office, and Major Competitors
Table 39. Ethris Major Business
Table 40. Ethris mRNA Cancer Vaccines and Therapeutics Product and Solutions
Table 41. Ethris mRNA Cancer Vaccines and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Tiba Biotechnology Corporate Information, Head Office, and Major Competitors
Table 43. Tiba Biotechnology Major Business
Table 44. Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Product and Solutions
Table 45. Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Global mRNA Cancer Vaccines and Therapeutics Revenue (USD Million) by Players (2019-2021)
Table 47. Global mRNA Cancer Vaccines and Therapeutics Revenue Share by Players (2019-2021)
Table 48. Breakdown of mRNA Cancer Vaccines and Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 49. mRNA Cancer Vaccines and Therapeutics Players Head Office, Products and Services Provided
Table 50. mRNA Cancer Vaccines and Therapeutics Mergers & Acquisitions in the Past Five Years
Table 51. mRNA Cancer Vaccines and Therapeutics New Entrants and Expansion Plans
Table 52. Global mRNA Cancer Vaccines and Therapeutics Revenue (USD Million) by Type (2016-2021)
Table 53. Global mRNA Cancer Vaccines and Therapeutics Revenue Share by Type (2016-2021)
Table 54. Global mRNA Cancer Vaccines and Therapeutics Revenue Forecast by Type (2021-2026)
Table 55. Global mRNA Cancer Vaccines and Therapeutics Revenue by Application (2016-2021)
Table 56. Global mRNA Cancer Vaccines and Therapeutics Revenue Forecast by Application (2021-2026)
Table 57. North America mRNA Cancer Vaccines and Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 58. North America mRNA Cancer Vaccines and Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 59. North America mRNA Cancer Vaccines and Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 60. North America mRNA Cancer Vaccines and Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 61. North America mRNA Cancer Vaccines and Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 62. North America mRNA Cancer Vaccines and Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 63. Europe mRNA Cancer Vaccines and Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 64. Europe mRNA Cancer Vaccines and Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 65. Europe mRNA Cancer Vaccines and Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 66. Europe mRNA Cancer Vaccines and Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 67. Europe mRNA Cancer Vaccines and Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 68. Europe mRNA Cancer Vaccines and Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 69. Asia-Pacific mRNA Cancer Vaccines and Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 70. Asia-Pacific mRNA Cancer Vaccines and Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 71. Asia-Pacific mRNA Cancer Vaccines and Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 72. Asia-Pacific mRNA Cancer Vaccines and Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 73. Asia-Pacific mRNA Cancer Vaccines and Therapeutics Revenue by Region (2016-2021) & (USD Million)
Table 74. Asia-Pacific mRNA Cancer Vaccines and Therapeutics Revenue by Region (2021-2026) & (USD Million)
Table 75. South America mRNA Cancer Vaccines and Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 76. South America mRNA Cancer Vaccines and Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 77. South America mRNA Cancer Vaccines and Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 78. South America mRNA Cancer Vaccines and Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 79. South America mRNA Cancer Vaccines and Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 80. South America mRNA Cancer Vaccines and Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 81. Middle East & Africa mRNA Cancer Vaccines and Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 82. Middle East & Africa mRNA Cancer Vaccines and Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 83. Middle East & Africa mRNA Cancer Vaccines and Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 84. Middle East & Africa mRNA Cancer Vaccines and Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 85. Middle East & Africa mRNA Cancer Vaccines and Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 86. Middle East & Africa mRNA Cancer Vaccines and Therapeutics Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. mRNA Cancer Vaccines and Therapeutics Picture
Figure 2. Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Type in 2020
Figure 3. Adeno Carcinomas
Figure 4. Mucinous Carcinomas
Figure 5. Adenosquamous Carcinomas
Figure 6. mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Application in 2020
Figure 7. Infectious Disease Picture
Figure 8. Cancer Picture
Figure 9. Others Picture
Figure 10. Global mRNA Cancer Vaccines and Therapeutics Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 11. Global mRNA Cancer Vaccines and Therapeutics Revenue and Forecast (2016-2026) & (USD Million)
Figure 12. Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Region (2016-2026)
Figure 13. Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Region in 2020
Figure 14. North America mRNA Cancer Vaccines and Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 15. Europe mRNA Cancer Vaccines and Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. Asia-Pacific mRNA Cancer Vaccines and Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. South America mRNA Cancer Vaccines and Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Middle East and Africa mRNA Cancer Vaccines and Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. mRNA Cancer Vaccines and Therapeutics Market Drivers
Figure 20. mRNA Cancer Vaccines and Therapeutics Market Restraints
Figure 21. mRNA Cancer Vaccines and Therapeutics Market Trends
Figure 22. Moderna Therapeutics Recent Developments and Future Plans
Figure 23. CureVac Recent Developments and Future Plans
Figure 24. Translate Bio Recent Developments and Future Plans
Figure 25. BioNTech Recent Developments and Future Plans
Figure 26. Sangamo Therapeutics Recent Developments and Future Plans
Figure 27. Argos Therapeutics Recent Developments and Future Plans
Figure 28. In-Cell-Art Recent Developments and Future Plans
Figure 29. eTheRNA Recent Developments and Future Plans
Figure 30. Ethris Recent Developments and Future Plans
Figure 31. Tiba Biotechnology Recent Developments and Future Plans
Figure 32. Global mRNA Cancer Vaccines and Therapeutics Revenue Share by Players in 2020
Figure 33. mRNA Cancer Vaccines and Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 34. Global Top 3 Players mRNA Cancer Vaccines and Therapeutics Revenue Market Share in 2020
Figure 35. Global Top 10 Players mRNA Cancer Vaccines and Therapeutics Revenue Market Share in 2020
Figure 36. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 37. Global mRNA Cancer Vaccines and Therapeutics Revenue Share by Type in 2020
Figure 38. Global mRNA Cancer Vaccines and Therapeutics Market Share Forecast by Type (2021-2026)
Figure 39. Global mRNA Cancer Vaccines and Therapeutics Revenue Share by Application in 2020
Figure 40. Global mRNA Cancer Vaccines and Therapeutics Market Share Forecast by Application (2021-2026)
Figure 41. North America mRNA Cancer Vaccines and Therapeutics Sales Market Share by Type (2016-2026)
Figure 42. North America mRNA Cancer Vaccines and Therapeutics Sales Market Share by Application (2016-2026)
Figure 43. North America mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Country (2016-2026)
Figure 44. United States mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Canada mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Mexico mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Europe mRNA Cancer Vaccines and Therapeutics Sales Market Share by Type (2016-2026)
Figure 48. Europe mRNA Cancer Vaccines and Therapeutics Sales Market Share by Application (2016-2026)
Figure 49. Europe mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Country (2016-2026)
Figure 50. Germany mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. France mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. United Kingdom mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Russia mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Italy mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Asia-Pacific mRNA Cancer Vaccines and Therapeutics Sales Market Share by Type (2016-2026)
Figure 56. Asia-Pacific mRNA Cancer Vaccines and Therapeutics Sales Market Share by Application (2016-2026)
Figure 57. Asia-Pacific mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Region (2016-2026)
Figure 58. China mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Japan mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. South Korea mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. India mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Southeast Asia mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Australia mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. South America mRNA Cancer Vaccines and Therapeutics Sales Market Share by Type (2016-2026)
Figure 65. South America mRNA Cancer Vaccines and Therapeutics Sales Market Share by Application (2016-2026)
Figure 66. South America mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Country (2016-2026)
Figure 67. Brazil mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. Argentina mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Middle East and Africa mRNA Cancer Vaccines and Therapeutics Sales Market Share by Type (2016-2026)
Figure 70. Middle East and Africa mRNA Cancer Vaccines and Therapeutics Sales Market Share by Application (2016-2026)
Figure 71. Middle East and Africa mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Country (2016-2026)
Figure 72. Turkey mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Saudi Arabia mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. UAE mRNA Cancer Vaccines and Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Methodology
Figure 76. Research Process and Data Source
世界のmRNAワクチンおよび治療薬市場予測（～2024年）：企業別、地域別、種類・用途別 Scope of the Report: The global mRNA Vaccine And Therapeutics market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, especially in Ch…- 世界のRNAワクチン市場予測（～2024年）：メーカー別、地域別、種類・用途別 RNA is a rather versatile technology and offers a number of advantages. RNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes RNA especially attractive for vaccines and gene editing. RNA is well defined chemically which …
- 世界の血液がん治療市場 2021：企業別、地域別、種類・用途別 The Blood Cancer Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regul…
- 世界の新興癌ワクチン市場予測（～2024年）：メーカー別、地域別、種類・用途別 Genetic vaccines are emerging as promising methodologies to elicit immune responses against a wide variety of antigens. Scope of the Report: The worldwide market for Emerging Cancer Vaccines is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, fro…
- 世界の新興癌ワクチン市場予測（～2024年）：メーカー別、地域別、種類・用途別 Genetic vaccines are emerging as promising methodologies to elicit immune responses against a wide variety of antigens. Scope of the Report: The worldwide market for Emerging Cancer Vaccines is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, fro…